Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dipeptide mimetics of ngf and bdnf neurotrophins

a neurotrophin and dipeptide technology, applied in the field of bioorganic chemistry, can solve the problems of rapid degradation of neurotrophins in the bloodstream, development of pain syndrome upon their use, and failure of neurotrophin drugs

Inactive Publication Date: 2011-12-22
UCHREZHDENIE ROSSIJSKOJ AKADI MEDITSINSKIKH NAUK NAUCHNO ISSLEDOVATELSKIJ INST FARMAKOLOGII IMENI V V ZAKUSOVA RAMN
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021]The compounds having a neuroprotective activity can increase the phosphorylation of tyrosine kinases and the amount of the heat shock proteins Hsp32 and / or Hsp70.

Problems solved by technology

In fact, however, neurotrophins were unsuccessful drugs because, being proteins, they are unavailable orally, unable to cross the blood-brain barrier and other biological barriers and are rapidly degraded in the bloodstream.
A considerable drawback of neurotrophins is the development of pain syndrome upon their use.
The compounds described in the references cited above, however, neither disclose nor suggest any novel structural variations of the claimed compounds.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dipeptide mimetics of ngf and bdnf neurotrophins
  • Dipeptide mimetics of ngf and bdnf neurotrophins
  • Dipeptide mimetics of ngf and bdnf neurotrophins

Examples

Experimental program
Comparison scheme
Effect test

example 1

The Synthesis of N-monosuccinyl-glutamyl-lysine amide, HOOC(CH2)2CO-Glu-Lys-NH2 (GK-1)

a) The Preparation of N-benzyloxycarbonyl-γ-t-butyl-glutamyl-Nε-t-butyloxycarbonyl-lysine amide, Z-Glu(OBut)-Lys(Boc)-NH2

[0137]A solution of 4.0 g (8.4 mmol) N-benzyloxycarbonyl-Nε-tert-butyloxycarbonyl-lysine N-oxysuccinimide ester (Z-Lys(Boc)-OSu) in 20 ml DMFA was treated with 2 ml conc. ammonia for 5 min followed by dilution with water, and the precipitated N-benzyloxycarbonyl-Nε-tert-butyloxycarbonyl-lysine amide (Z-Lys(Boc)-NH2) was filtered off. The resulting product was dissolved in methanol, then 3.0 g of 10% Pd / C was added and hydrogenated at room temperature. The catalyst was filtered off, the solvent was removed in vacuo, and the residue was taken up in 20 ml DMFA. To this solution 3.9 g (9.0 mmol) N-benzyloxycarbonyl-γ-t-butyl-glutamic acid N-oxysuccinimide ester (Z-Glu(OBut)-OSu) was added. The reaction mixture was stirred for 6 h at room temperature (TLC control), then 2 ml DMPDA w...

example 2

The Synthesis of bis-(N-monosuccinyl-glutamyl-lysine)hexamethylenediamide, (HOOC(CH2)2CO-Glu-Lys-NH)2—(CH2)6 (GK-2)

a) The Preparation of bis-(N-benzyloxycarbonyl-Nε-t-butyloxycarbonyl-lysine)hexamethylenediamide, (Z-Lys(Boc)-NH)2—(CH2)6

[0141]A solution of 4.3 g (9.0 mmol) N-benzyloxycarbonyl-Nε-t-butyloxycarbonyl-lysine N-oxysuccinimide ester (Z-Lys(Boc)-OSu) and 0.5 g (4.3 mmol) hexamethylenediamine in 20 ml DMFA was stirred for 4 h at room temperature, forming a cloudy solution. The reaction mixture was diluted with 80 ml water and allowed to stand for a few hours. The solidified precipitate was filtered off and washed with water. It was used without drying.

b) The Preparation of bis-(N-benzyloxycarbonyl-γ-t-butyl-glutamyl-Nε-t-butyloxycarbonyl-lysine)hexamethylenediamide, (Z-Glu(OBut)-Lys(Boc)-NH)2—(CH2)6

[0142]The (Z-Lys(Boc)-NH)2—(CH2)6 prepared in (a) was hydrogenated in methanol over 10% Pd / C at room temperature. When the starting compound disappeared (TLC control), the ca...

example 3

The Synthesis of N-acetyl-lysyl-glutamic acid amide, CH3CO-Lys-Glu-NH2 (GK-3)

a) The Preparation of γ-benzyl-glutamic acid amide, H-Glu(OBzl)-NH2

[0146]8.0 g (17.4 mmol) of N-t-butyloxycarbonyl-γ-benzyl-glutamic acid p-nitrophenyl ester (Boc-Glu(OBzl)-ONp) were dissolved in 30 ml DMFA, 3.5 ml aqueous ammonia was added and allowed to stand for 5 min. Then to the reaction mixture 100 ml water, 50 ml diethyl ether and 100 ml of hexane were added and allowed to stand at +5° C. for a few hours. The precipitate was filtered off, and the solid residue was washed with water and hexane. The resulting product was dissolved in 80 ml TFA, and the solution was kept for 1 h at room temperature. The solvent was removed in vacuo, and the residue was allowed to crystallize with ether. The residue that crystallized gradually was filtered off and washed with ether to yield 5.8 g (96%) of the product. M.p. 68-70° C., [α]6D+10.0° (c=0.3; water-ethanol, 1:2).

b) The Preparation of N-t-butyloxycarbonyl-Nε-b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10−9 to 10−5 M. They also displayed neuroprotective, anti-parkinsonian, anti-stroke, anti-ischemic, anti-depressant and anti-amnestic activities in animal models and were active in experimental models of Alzheimer's disease. These in vivo effects of the claimed compounds are displayed in the dose range of 0.01 to 10 mg / kg when administered intraperitoneally.

Description

FIELD OF THE INVENTION[0001]The invention relates to the field of bioorganic chemistry, namely to novel substituted dipeptides that are mimetics of the neurotrophic factors, which can be useful as pharmaceutical agents for the regulation of growth, differentiation, survival and programmed neuronal cell death. More specifically, this invention relates to monomeric and dimeric dipeptide mimetics of the NGF and BDNF loop regions, which can be useful for the treatment of neurodegenerative diseases including Parkinson's and Alzheimer's diseases, Huntington's chorea, stroke, cerebral ischemia, cerebral traumas, depression etc.BACKGROUND OF THE INVENTION[0002]Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are members of the neurotrophin family which can improve neuronal survival and prevent neurodegeneration resulting from disease or trauma. Sensory, sympathetic and cholinergic neurons are sensitive to NGF. Therapy using NGF is assumed to prevent the development of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/07C07K5/113C07K5/11A61P25/24C07C323/59A61P25/16A61P25/28A61P25/00C07C237/22C07K5/103
CPCA61K38/00C07K5/06C07K5/06026C07K5/06113C07K5/06078C07K5/06086C07K5/06104C07K5/0606A61P25/00A61P25/16A61P25/24A61P25/28C07K5/02C07K5/06069
Inventor SEREDENIN, SERGEY BORISOVICHGUDASHEVA, TATYANA ALEXANDROVNA
Owner UCHREZHDENIE ROSSIJSKOJ AKADI MEDITSINSKIKH NAUK NAUCHNO ISSLEDOVATELSKIJ INST FARMAKOLOGII IMENI V V ZAKUSOVA RAMN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com